ClinicalTrials.gg
CompletedNCT03606408Updated Dec 18, 2024Results posted

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

A Phase 2 interventional study of osilodrostat in Cushing's Syndrome, sponsored by RECORDATI GROUP. Completed at 56 sites in 21 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by RECORDATI GROUP · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 58 studies in Cushing Syndrome with a site in United States — 14 open to participants now, 17 under way, none of them phase 3. Cushing Syndrome · United States.

Enrollment
6th of 34
127 · median 35
Started
2018
with 3 others
Phase 2
17 of 58
7 open now
Registered
36th of 58
by date
Lead sponsor
4 of 58
RECORDATI GROUP

Among the 58 studies in Cushing Syndrome with a site in United States, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2018, is one of 17 in phase 2, and was the 36th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

14 of the 58 studies in Cushing Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Cushing Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.

Read the detailed description

There will be no screening period for this study. Eligible subjects can start their treatment with osilodrostat as soon as they are enrolled in the study. The first study visit will be scheduled at the time of the last study visit for the parent study. Subjects must return to the study center at least on a quarterly basis (every 12 weeks ± 2 weeks) for safety and clinical benefit assessments, and resupply of study medication. Drug dispensing and administration information and adverse events will be collected. The subject may return to the clinic at any given time as per standard of care or treating physician recommendation; however, only the quarterly study visits will be recorded in the Case Report Form (CRF). Study medication dispensed will be recorded in the CRF dose administration page.

All adverse events and serious adverse events, including pregnancy, will be collected throughout the study. Subjects will continue to be treated in this roll-over study until they are no longer benefiting from their osilodrostat treatment as judged by the Investigator or until osilodrostat is commercially available or until one of other discontinuation criteria is met.

03

Conditions studied

  • Cushing's Syndrome

Browse trials for

Keywords

  • Cushing's syndrome
  • osilodrostat
  • LCI699
  • endogenous Cushing's syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is currently participating in a Global Novartis-sponsored study receiving osilodrostat for any type of endogenous CS and has fulfilled all their requirements in the parent study.
  • Patient is currently benefiting from treatment with osilodrostat, as determined by the Investigator.
  • Patient has demonstrated compliance, as assessed by the Investigator, with the parent study protocol requirements.
  • Willingness and ability to comply with scheduled visits and treatment plans.
  • Written obtained prior to enrolling into the roll-over study before evaluating the applicability of the subject's participating in the study. -- If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.

Exclusion criteria

Exclusion Criteria:

  • Patient has been permanently discontinued from osilodrostat study treatment in a parent Novartis-sponsor study.
  • Patients who are receiving osilodrostat in combination with unapproved or experimental treatments for any type of endogenous CS.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. Pregnant or nursing (lactating) women
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and for 1 week of study after stopping medication. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation. at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to baseline). The vasectomized male partner should be the sole partner for that subject
    • Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Other
    osilodrostat

    open label, with patients receiving same dose as provided in the parent study

    Drug: osilodrostat

Interventions

  • osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.

    Also known as: LCI699

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse/Serious Adverse Events

    To evaluate long-term safety data with osilodrostat treatment (Frequency and severity of adverse events (AEs)/serious adverse events (SAEs))

    Time frame: up to 5 years

Secondary outcomes

  1. Percentage of Patients With Clinical Benefit

    Proportion of patients with clinical benefit as assessed by the Investigator at scheduled visits based on medical check-up and lab values such as Urine Free Cortisol.

    Time frame: up to of 5 years

07

Results

Posted Dec 18, 2024

Participant flow

There was no screening period for the study, eligible patients were able to start study treatment as soon as they were enrolled. The study was conducted for 5 years from first patient first visit. Patients continued to be treated in this roll-over study until they no longer received clinical benefit from treatment with osilodrostat (as judged by the Investigator), until osilodrostat was commercially available in their country, or until one of the other discontinuation criteria were met.

Participant flow — Overall Study
MilestoneOsilodrostat
Started127
Completed99
Not completed28
Withdrew: Adverse event13
Withdrew: Withdrawal by subject7
Withdrew: Physician decision4
Withdrew: Lack of efficacy2
Withdrew: Death1
Withdrew: New therapy for study indication1

Outcome measures

PrimaryNumber of Participants With Adverse/Serious Adverse Events

To evaluate long-term safety data with osilodrostat treatment (Frequency and severity of adverse events (AEs)/serious adverse events (SAEs))

Time frame:
up to 5 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse/Serious Adverse Events
ParticipantsOsilodrostat
Adverse events (AEs)115
Treatment-related AEs50
Adverse events of CTCAE Grade ≥ 334
Treatment-related AEs of CTCAE Grade ≥ 33
Serious adverse events35
Treatment-related SAEs4
Fatal SAEs2
Treatment-related fatal SAEs0
Adverse events leading to discontinuation14
Treatment-related AEs leading to discontinuation5
Adverse events leading to dose interruption or adjustment56
Treatment-related AEs leading to dose interruption or adjustment35
Adverse events requiring additional therapy94
Treatment-related AEs requiring additional therapy17
Adverse events of special interest (AESIs)51
Treatment-related AESIs29
SecondaryPercentage of Patients With Clinical Benefit

Proportion of patients with clinical benefit as assessed by the Investigator at scheduled visits based on medical check-up and lab values such as Urine Free Cortisol.

Time frame:
up to of 5 years
Reported as:
Count of participants · Participants
Percentage of Patients With Clinical Benefit
ParticipantsOsilodrostat
Week 1127
Week 12122
Week 24119
Week 36114
Week 48103
Week 9674
Week 14452
End of treatment99

Adverse events

Collected over From enrolment up to 30 days after the last administration of study treatment (up to 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osilodrostat2/127 (1.6%)35/127 (27.6%)115/127 (90.6%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventOsilodrostat
COVID-19Infections and infestations7/127
CholelithiasisHepatobiliary disorders3/127
Pitituary tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/127
Adrenal insufficiencyEndocrine disorders2/127
ACTH-producing pituitary tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/127
Acute stress disorderPsychiatric disorders1/127
Adenocarcinoma pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/127
Alanine aminotransferase increasedInvestigations1/127
AppendicitisInfections and infestations1/127
Aspartate aminotransferase increasedInvestigations1/127
Most frequent other events
Showing 10 of 24
Most frequent other events
EventOsilodrostat
COVID-19Infections and infestations29/127
Adrenal insufficiencyEndocrine disorders16/127
HeadacheNervous system disorders16/127
NauseaGastrointestinal disorders14/127
DiarrhoeaGastrointestinal disorders13/127
Cortisol free urine increasedInvestigations13/127
SARs-Cov-2 test positiveInvestigations13/127
NasopharyngitisInfections and infestations12/127
HypertensionVascular disorders11/127
InfluenzaInfections and infestations11/127

Baseline characteristics

The starting dose of this roll-over study was the same as the one the patients were taking at the end of the parent studies. In addition, they underwent to dose adjustment according to the urine cortisol level and possible AEs. The daily dosage ranged from 1mg every 3 days to 30mg twice a day. So it is not feasible to report the results according to the drug dosage and data has been analysed as one arm.

Age, Continuous
Age, Continuous(years)Osilodrostat
Mean44.2 ± 12.39
Age, Customized
Age, Customized(Participants)Osilodrostat
<65 years119
≥65 years8
Sex: Female, Male
Sex: Female, Male(Participants)Osilodrostat
Female95
Male32
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Osilodrostat
Hispanic or Latino14
Not Hispanic or Latino94
Unknown or Not Reported19
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Osilodrostat
American Indian or Alaska Native0
Asian26
Native Hawaiian or Other Pacific Islander0
Black or African American4
White96
More than one race0
Unknown or Not Reported1
Weight
Weight(kg)Osilodrostat
Mean74.59 ± 21.253
Height
Height(cm)Osilodrostat
Mean163.73 ± 9.839
Body Mass Index
Body Mass Index(Kg/m^2)Osilodrostat
Mean27.84 ± 7.631
08

Study locations

56 sites
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Emory University School of Medicine G2304 - C2301
    Atlanta, Georgia 30322, United States
  • Northwestern University SC - LCI699C2301
    Chicago, Illinois 60611, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Columbia University Medical Center New York Presbyterian Neuroendocrine Unit
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania Medical Center Univ Penn
    Philadelphia, Pennsylvania 19104, United States
  • Medical College of Wisconsin MCW 2
    Milwaukee, Wisconsin 53226, United States
  • Sanatorio Guemes
    Caba, Buenos Aires C1180AAX, Argentina
  • Universitaetsklinik fuer Innere Medizin III
    Vienna, A-1090, Austria
  • Gasthuisberg University Hospital
    Leuven, 3000, Belgium
  • Universidade Federal do Ceara
    Fortaleza, CE 60020-181, Brazil
  • Hospital Universitario Clementino Fraga Filho
    Rio de Janeiro, RJ 21941-913, Brazil
  • Hospital do Servidor Publico Estadual de Sao Paulo
    Sao Paulo, SP 04039 004, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da USP
    Sao Paulo, SP 05403 000, Brazil
  • USHATE Akad Ivan Penchev
    Sofia, 1431, Bulgaria
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 1V7, Canada
  • Centre de recherche du CHUM CRCHUM
    Montreal, Quebec H2W 1T8, Canada
  • CHUS Hopital Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • The First Affiliated Hopsital, Sun Yat-Sun University
    Guangzhou, Guangdong 510080, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Clinica Los Yoses
    San Pedro, San Jose, Costa Rica 1406 1200, Costa Rica
  • CHU de Bordeaux
    Pessac, Cedex 33604, France
  • Hopital Kremlin Bicetre
    Le Kremlin Bicetre, 94275, France
  • CHRU de Lille
    Lille Cedex, 59037, France
  • Hopital Cochin
    Paris, 75014, France
  • Universitaetsklinikum Erlangen Nuernberg
    Erlangen, 91054, Germany
  • Universitaetsklinikum Muenchen LMU
    Muenchen, 81377, Germany
  • All India Institute of Medical Sciences
    New Delhi, 110029, India
  • AOU Osp Riuniti Umberto I GM Lancisi G Salesi Univ Studi
    Ancona, AN 60126, Italy
  • Azienda Ospedaliera di Padova Università degli Studi
    Padova, PD 35128, Italy
  • Az Ospedaliero Universitaria Pisana Pres Osped di Cisanello
    Pisa, PI 56124, Italy
  • A O Universitaria Policlinico Federico II Univ Studi Fed II
    Napoli, 80131, Italy
  • National Hospital Organization Nagoya Medical Center
    Nagoya, Aichi 460-0001, Japan
  • Hyogo College of Medicine Hospital
    Nishinomiya, Hyogo 663 8501, Japan
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Yonsei Univ Health System YUCM
    Seoul, 03722, Korea, Republic of
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • SP ZOZ Szpital Uniwersytecki w Krakowie
    Krakow, 31-501, Poland
  • Mazowiecki Szpital Brodnowski
    Warszawa, 03 242, Poland
  • Center for Endocrinology Russian Academy of Med Sciences
    Moscow, 117036, Russian Federation
  • Hospital Universitario Virgen del Rocio
    Sevilla, Andalucia 41013, Spain
  • Complejo Uni. Hosp. A Coruña ( antes Hospital Juan Canalejo)
    La Coruna, Galicia 15006, Spain
  • Hospital Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Universitario i Politecnico La Fe
    Valencia, 46026, Spain
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Siriraj Hospital
    Bangkok, 10700, Thailand
  • Songklanagarind Hospital Endocrinology and Metabolism
    Songkla, 90110, Thailand
  • Istanbul University Cerrahpasa Faculty of Medicine
    Istanbul, TUR 34098, Turkey
  • Marmara University Medical Faculty
    Altunizade, 34662, Turkey
  • Kocaeli University Medical Faculty
    Kocaeli, 41380, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Nov 2023, 61 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2018
First posted
Jul 30, 2018
StartActual
Oct 5, 2018
Primary completionActual
Nov 16, 2023
CompletionActual
Nov 16, 2023
Results first posted
Dec 18, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03606408
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Oct 5, 2018
Primary completion
Nov 16, 2023
Completion
Nov 16, 2023
Results posted
Dec 18, 2024
Last update
Dec 18, 2024

Study contacts

Recordati
study director · Recordati AG

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion